SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Spectrum Pharmaceuticals, Inc. Initiates Phase 3 Study of ZEVALIN® in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL); Most Common Form of Aggressive Non-Hodgkin's Lymphoma
Your Message